このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Ocuphire Pharma マネジメント

マネジメント基準チェック /14

Ocuphire Pharma'sの CEO はGeorge Magrathで、 Nov2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 3.15Mで、 3%給与と97%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.12%を直接所有しており、その価値は$ 40.24K 。経営陣と取締役会の平均在任期間はそれぞれ0.8年と3.8年です。

主要情報

George Magrath

最高経営責任者

US$3.1m

報酬総額

CEO給与比率	3.0%
CEO在任期間	less than a year
CEOの所有権	0.1%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Aug 19

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Jul 24

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Jul 12

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Sep 08

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Aug 12

Ocuphire extends IP rights for lead candidate with new U.S. patent

Aug 03

Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics

Jun 29

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jun 24

Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?

Mar 22

Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Oct 08

Ocuphire Pharma: An Undervalued Ophthalmic Play

Aug 05

Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma

Jun 17

Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans

Jun 11

Ocuphire drops 11% on $15M at-the money direct offering

Jun 04

Ocuphire Pharma EPS beats by $0.36

May 07

Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?

Feb 08

Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition

Jan 06

Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances

Jan 05

CEO報酬分析

Ocuphire Pharma の収益と比較して、George Magrath の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

報酬と市場: Georgeの総報酬 ($USD 3.15M ) は、 US市場 ($USD 680.04K ) の同規模の企業の平均を上回っています。

報酬と収益: Georgeの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

George Magrath (40 yo)

less than a year

在職期間

US$3,146,518

報酬

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Ocuphire Pharma, Inc. since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sect...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
George Magrath	CEO & Director	less than a year	US$3.15m	0.11% $ 41.7k
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.41% $ 149.8k
Jay Pepose	Chief Medical Advisor & Director	no data	US$662.10k	0.28% $ 100.5k
Amy Zaremba Rabourn	Senior Vice President of Finance	no data	US$789.92k	0.029% $ 10.7k
Nirav Suresh Jhaveri	Chief Financial Officer	less than a year	データなし	0.57% $ 208.5k
Joseph Schachle	Chief Operating Officer	less than a year	データなし	0.0076% $ 2.8k
Ashwath Jayagopal	Chief Scientific & Development Officer	less than a year	データなし	0.30% $ 109.1k
Bindu Manne	Head of Market Development & Commercialization	2.7yrs	データなし	データなし
Erik Sims	Director & Corporate Controller	no data	データなし	データなし

0.8yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: OCUPの経営陣は経験豊富とはみなされません ( 0.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
George Magrath	CEO & Director	less than a year	US$3.15m	0.11% $ 41.7k
Jay Pepose	Chief Medical Advisor & Director	3.3yrs	US$662.10k	0.28% $ 100.5k
James S. Manuso	Independent Director	3.8yrs	US$154.81k	0.35% $ 126.3k
David Boyer	Member of Medical Advisory Board	no data	データなし	データなし
Richard Rodgers	Independent Director	3.8yrs	US$1.35m	0.62% $ 226.6k
Jeffrey Heier	Member of Medical Advisory Board	no data	データなし	データなし
Peter Kaiser	Member of Medical Advisory Board	4.7yrs	データなし	データなし
Susan Benton	Independent Director	3.8yrs	US$135.34k	0.38% $ 137.4k
Cameron Gallagher	Independent Chairman	3.8yrs	US$174.62k	0.14% $ 49.9k
Sean Ainsworth	Lead Independent Director	3.8yrs	US$149.56k	0.18% $ 65.6k
David Lally	Member of Medical Advisory Board	2.8yrs	データなし	データなし
David Brown	Member of Medical Advisory Board	2.8yrs	データなし	データなし

3.8yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: OCUPの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Ocuphire Pharma マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Recent updates

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Consensus revenue estimates increase by 62%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 12% to US$17.25

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Full year 2023 earnings: EPS and revenues miss analyst expectations

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 17%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Consensus revenue estimates increase by 24%

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 16%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Consensus revenue estimates fall by 15%

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

Price target decreased by 7.8% to US$20.75

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 31%

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Consensus revenue estimates increase by 45%

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Price target decreased by 12% to US$20.40

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire Pharma, Inc. Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol and Strategic Partnership with American Society of Ophthalmic Administrators

We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully

Ocuphire Expands Medical Advisory Board with Seven New Kols and Strengthens Leadership Team

Ocuphire Pharma, Inc. Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Ocuphire extends IP rights for lead candidate with new U.S. patent

Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Ocuphire Pharma, Inc. to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics At Annual Macula Society Meeting

Ocuphire Pharma, Inc., Annual General Meeting, Jun 13, 2022

Founder recently bought US$51k worth of stock

Ocuphire Pharma, Inc. Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

High number of new directors

No longer forecast to breakeven

Ocuphire Pharma, Inc. Appoints Jay Pepose as Chief Medical Advisor

Ocuphire Pharma, Inc. Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

No longer forecast to breakeven

Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

Ocuphire Pharma, Inc. Provides Update on its APX3330 and Nyxol Clinical Programs

Ocuphire Pharma, Inc. Initiates Enrollment of Nyxol Mira-4 Pediatric Study in Rm Per Agreed Initial Pediatric Study Plan with FDA

マネジメント基準チェック /14